BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 26971843)

  • 1. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
    Baumann T; Rottenburger C; Nicolas G; Wild D
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
    Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
    Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
    Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions.
    Deroose CM; Hindié E; Kebebew E; Goichot B; Pacak K; Taïeb D; Imperiale A
    J Nucl Med; 2016 Dec; 57(12):1949-1956. PubMed ID: 27811124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
    Sclafani F; Carnaghi C; Di Tommaso L; Rodari M; Destro A; Rimassa L; Giordano L; Chiti A; Roncalli M; Santoro A
    Tumori; 2011; 97(5):620-8. PubMed ID: 22158494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
    Papadakis GZ; Karantanas AH; Marias K; Millo C
    Eur J Radiol; 2021 Oct; 143():109932. PubMed ID: 34482177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
    Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
    J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Correlation Between [
    Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
    Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.
    Flechsig P; Zechmann CM; Schreiweis J; Kratochwil C; Rath D; Schwartz LH; Schlemmer HP; Kauczor HU; Haberkorn U; Giesel FL
    Eur J Radiol; 2015 Aug; 84(8):1593-1600. PubMed ID: 25999064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Prognostic Value of PET/CT Imaging with Combination of
    Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
    Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge.
    Granata V; Fusco R; Setola SV; Castelguidone ELD; Camera L; Tafuto S; Avallone A; Belli A; Incollingo P; Palaia R; Izzo F; Petrillo A
    Radiol Oncol; 2019 Oct; 53(4):373-387. PubMed ID: 31652122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current role of Nuclear Medicine in the diagnosis and therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Georgakopoulos A
    Hell J Nucl Med; 2023; 26 Suppl():49-51. PubMed ID: 37658564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
    J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
    Giammarile F; Billotey C; Lombard-Bohas C; Le Bars D; Bournaud C; Masson S; Walter T; Houzard C; Scoazec JY; Hervieu V; Vuillez JP; Cornu C; Janier M; Borson-Chazot F
    Nucl Med Commun; 2011 Feb; 32(2):91-7. PubMed ID: 21076344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
    Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
    Saleh M; Bhosale PR; Yano M; Itani M; Elsayes AK; Halperin D; Bergsland EK; Morani AC
    Abdom Radiol (NY); 2022 Sep; 47(9):3078-3100. PubMed ID: 33095312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen.
    Adams S; Baum RP; Hertel A; Schumm-Dräger PM; Usadel KH; Hör G
    Nucl Med Commun; 1998 Jul; 19(7):641-7. PubMed ID: 9853344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.